AT-1501

Phase 2Small molecule

EEledon Pharmaceuticals

AT-1501 is one of 65 small molecule programs targeting Kidney Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Iga NephropathyActive, not recruiting

Kidney TransplantPhase 1/Phase 2

Active, not recruiting

Iga NephropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Simulect

Novartis

Preclinical

15 3

Medrol

Pfizer

Preclinical

12 4

Zemplar

AbbVie

Preclinical

2 5

Radicava

Shionogi

Preclinical

1 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Sensipar

Amgen

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 9

AT-1501

EEledon Pharmaceuticals

Phase 2

3 10

Jardiance

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Kidney Transplant

NCT05027906

Clinical

Trials by Indication[1]

Kidney Transplant3 trials

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Completed·EEledon Pharmaceuticals·Phase 2·NCT05983770·127 enrolled

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Recruiting·EEledon Pharmaceuticals·Phase 1/2·NCT05027906·48 enrolled

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Enrolling by invitation·EEledon Pharmaceuticals·Phase 2·NCT06126380·132 enrolled

Islet Cell Transplantation1 trial

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

Withdrawn·AAnelixis Therapeutics, LLC·Phase 2·NCT04711226

Immunomodulation1 trial

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

Withdrawn·EEledon Pharmaceuticals·Phase 1/2·NCT05480657

IgA Nephropathy1 trial

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Terminated·EEledon Pharmaceuticals·Phase 2·NCT05125068·24 enrolled

Adult1 trial

Multiple Doses of AT-1501-A201 in Adults With ALS

Completed·AAnelixis Therapeutics, LLC·Phase 2·NCT04322149·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for AT-1501. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AT-1501 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AT-1501. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eledon Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEledon Pharmaceuticals

AT-1501

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Kidney Transplant3 trials

Islet Cell Transplantation1 trial

Immunomodulation1 trial

IgA Nephropathy1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News